United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - etoricoxib - oral tablet - 30mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rituximab -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - rituximab -

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - clonazepam - tablets - clonazepam 0.5 mg - clonazepam - clonazepam - typical or atypical petit mal, lennox - gastaut syndrome (petit mal variant), generalized primary or secondary tonic-clonic seizures including grand mal and focal seizures. panic disorder.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - clonazepam - tablets - clonazepam 2 mg - clonazepam - clonazepam - typical or atypical petit mal, lennox - gastaut syndrome (petit mal variant), generalized primary or secondary tonic-clonic seizures including grand mal and focal seizures. panic disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; benzyl alcohol; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone hhh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone hhh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - phenytoin sodium - oral capsule - 100mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - adalimumab -